Makale

Akciğer kanseri erken teşhiste şifa buluyor

Kanser hastalığı, sinsi bir hastalıktır.. Pat diye çıkabilir.. Özellikle de akciğer  kanseri.. Akciğer kanserinin erken tanısı için güçlü bir tarama tetkiki yoktur.. Ama belli bir düzeyin üzerinde sigara içen bireyleri 55 yaşının üzerinde tomografiyle taramak istiyoruz.. Erken olarak yakalanırsa, cerrahi müdahale yapılabiliyor. Meme kanseri erken tanısı için mamografi, kalın barsak kanseri erken tanısı için kolonoskopi…

Devamını Oku
Makale

Meme, prostat ve jinekolojik kanserlerde uygulanan hormon tedavilerinde yan etkilere dikkat edilmeli

Meme kanseri, prostat kanseri ve jinekolojik kanserlerin tedavilerinde hormon tedavileri uygulanabiliyor. Pandemi döneminde de aksatılmaması gereken hormon tedavisini alınırken yan etki tedavilerinin ihmal edilmemesi gerektiğini belirten Anadolu Sağlık Merkezi Medikal Onkoloji Uzmanı Prof. Dr. Serdar Turhal, “Eğer bir kanser hücresinin çoğalmasında hormonların etkisi varsa (prostat kanseri, meme kanseri, jinekolojik kanserler) hormon tedavileri ya da anti…

Devamını Oku
Makale

2019 – Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Obesity is a well-known carcinogenic factor for colorectal cancer [1, 2]. However, the relationship between obesity and malignancy is still not well understood. Obesity can cause production of VEGF, angiopoietin-2, and other growth factors that induce tumor growth [3, 4]. It can also cause insulin resistance, hyperinsulinemia, and increased production of adipokines and proinflamatory cytokines…

Devamını Oku
Makale

2018 – Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common cancer amongman and seventh among woman and ranked as the third most common cause of cancer-related deaths [1, 2]. Chronic liver injury, Hepatitis B (HBV) and C (HCV) virus infections, alcohol-associated diseases, and aflatoxin intoxications are the leading causes of HCC development. Several mutations affecting WNT/𝛽-Catenin, PI3K/RAS,…

Devamını Oku
Makale

2017 – Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Efforts to improve outcomes beyond those achieved with 1 year of trastuzumab in patients with early-stage HER2-positive breast cancer are ongoing. Several different approaches, including extending the duration of trastuzumab to 2 years (HERceptin Adjuvant [HERA] trial),5 concurrent or sequential administration of lapatinib, a tyrosine kinase inhibitor, with trastuzumab (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation…

Devamını Oku
Makale

2016 – Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers.1 On admission, one-third of patients with RCC are at the metastatic stage.2 Chemotherapy resistance is very high in patients with RCC.3 Only a limited subset of patients ( 20%) benefit from cytokine therapy.4-7 It has been shown that the median progressionfree survival (PFS) was…

Devamını Oku